AbbVie And Pfizer: Q3 Dividend Checkup Post-Earnings

Summary:

• I review both AbbVie and Pfizer’s recent earnings reports via the window of dividends following Peter Lynch’s wisdom.
• Lynch’s insights into dividend stocks are often in the shadow of his reputation as a legendary growth investor.
• These insights, when overlooked, are an unfortunate loss for dividend investors.
• The review has resulted in an upgrade of ABBV stock and a downgrade of PFE stock.
• The contrast in the PEGY ratio and recent changes in their buyback programs are especially noteworthy.

ABBV and PFE stock: previous thesis and Q3 recap

I last wrote on AbbVie Inc. (NYSE:ABBV) back in September 2024 and on Pfizer Inc. (NYSE:PFE) back in August 2024. These articles are titled “AbbVie: Dividend Discount

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

As you can tell, our core style is to provide actionable and unambiguous ideas from our independent research. If your share this investment style, check out Envision Early Retirement. It provides at least 1x in-depth articles per week on such ideas.

We have helped our members not only to beat S&P 500 but also avoid heavy drawdowns despite the extreme volatilities in BOTH the equity AND bond market.

Join for a 100% Risk-Free trial and see if our proven method can help you too.